The Genes That Could Cancel Out a Fatal Diagnosis

TL;DR

For listenersOffer from Amazon

Turn your quiet moments into listening time

• Thousands of audiobooks, podcasts and originals
• Listen on your phone, tablet or Echo — also offline
• Cancel anytime

Try Audible free →Free trial for new members

As an affiliate, we earn on qualifying purchases.Hide

Researchers are identifying genetic variants that can counteract or lessen the severity of fatal inherited diseases. Recent studies and projects aim to harness these modifier genes for new therapies, offering hope for conditions once deemed incurable.

Scientists are making progress in identifying modifier genes that could potentially cancel out or mitigate the effects of fatal genetic conditions, such as Marfan syndrome. These discoveries could pave the way for new treatments that alter disease trajectories, offering hope to patients and families affected by inherited disorders.

Recent research has uncovered individuals who carry genetic mutations associated with severe diseases but remain healthy or exhibit mild symptoms. For example, a study examining over 500,000 genomes identified 13 adults who defied expectations by remaining healthy despite harboring mutations typically linked to early-onset or fatal conditions. Specifically, Romain Alderweireldt and Ludivine Verboogen, whose son was diagnosed with the neonatal form of Marfan syndrome, learned about these findings as part of efforts to find genetic variations that could explain such resilience.

Scientists are focusing on modifier genes, which can influence the severity or expression of inherited diseases. Successful examples include genes related to cholesterol regulation and sickle cell disease, where genetic variants have been harnessed to develop targeted therapies. The Icahn School of Medicine’s Resilience Project aims to expand this research by analyzing millions of genomes using advanced AI tools to identify protective genetic variants across hundreds of rare diseases. These efforts are now gaining momentum thanks to recent technological advances such as CRISPR gene editing.

Potential for New Therapies Using Modifier Genes

The identification of modifier genes offers the possibility of developing personalized treatments that could prevent or lessen the severity of inherited diseases. For families like Ludivine and Romain’s, this research provides hope that future interventions might allow children with genetic conditions to live healthier lives or even avoid deadly outcomes altogether. These discoveries could revolutionize how genetic diseases are managed, shifting the focus from treatment to prevention or mitigation through genetic modification.

Advances in Genetic Research and Past Discoveries

Over the past decade, scientists have increasingly identified genetic outliers—individuals who carry disease-causing mutations but remain healthy. Early studies in sickle cell disease and familial hypercholesterolemia demonstrated how modifier genes could influence disease severity. The recent pause and planned reboot of the Resilience Project reflect a broader scientific push to leverage new technologies like AI and CRISPR to find and manipulate these protective variants. The case of Romain and Ludivine’s son underscores the urgent need for such breakthroughs in conditions like Marfan syndrome, where early intervention can be life-saving.

“Within families, the disease can appear at very different ages and with starkly different severity, highlighting the influence of modifier genes.”

— Catherine Boileau, geneticist at INSERM

Unanswered Questions About Modifier Genes and Therapy Development

While promising, the precise mechanisms by which modifier genes influence disease outcomes are not yet fully understood. It remains unclear how many of these variants can be reliably identified and safely manipulated in humans. Additionally, translating these discoveries into effective, approved therapies will require extensive clinical testing, which could take years. The scope of potential side effects or unintended consequences of gene editing in this context is still under investigation.

Next Steps in Research and Clinical Application

Researchers plan to expand genomic analyses using AI tools to identify more protective variants across diverse populations. The rebooted Resilience Project aims to develop targeted gene therapies and test their safety and efficacy in clinical trials. For families like Ludivine and Romain’s, the hope is that future research will yield treatments that can alter the course of genetic diseases, transforming prognosis and quality of life. Expect ongoing studies and early-stage trials over the next several years to clarify the practical applications of these findings.

Key Questions

What are modifier genes?

Modifier genes are genetic variants that influence the severity, onset, or progression of inherited diseases, potentially reducing or neutralizing their effects.

Can modifier genes be used to treat diseases now?

Currently, research is ongoing, and while some therapies based on modifier genes are in development, most are not yet approved for widespread clinical use.

How might this research help families with genetic conditions?

Future therapies could allow for personalized treatments that prevent or lessen disease severity, potentially improving life expectancy and quality of life for affected individuals.

What are the risks of manipulating modifier genes?

Risks include unintended genetic changes and unforeseen side effects, which is why extensive testing and clinical trials are necessary before therapies are widely adopted.

When could these therapies become available?

It is uncertain; most therapies based on modifier genes are still in research or early clinical trial phases, and it may take several years before they are approved for general use.

Source: The Atlantic